ClinicalTrials.gg

Infertility clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,089 studies for Infertility across more than 10 countries. 355 are recruiting or about to start. 1,675 of them are mainly about Infertility (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 6 narrower conditions too, such as Infertility, Female: 2,825 studies, 517 open.

ClinicalTrials.gov finds 3,163 studies for Infertility. How that becomes 2,089 here

This page counts the studies the registry files under Infertility, and those it files under no condition that list Infertilitythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 3,163Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −720Filed under a narrower condition, counted on its own pageInfertility, Female 415 · Infertility, Male 226 · Oligospermia 30 · Azoospermia 16 · Asthenozoospermia 12 · Azoospermia, Nonobstructive 2
  3. −35List Infertility as a condition, but the registry did not file them under itMost often written as “Unexplained Infertility” (6), “Infertility Unexplained” (6), and “Female Infertility Due to Diminished Ovarian Reserve” (4). The registry filed them under other conditions only, most often Endometriosis (7) and Polycystic Ovary Syndrome (5).
  4. −319Match it another way72 name it in the title, 13 in a keyword, and 234 by a synonym or other text the search reads.
  5. 2,089The count on this page94 of them list Infertility in their own words; the registry filed them under no condition.

Status

Completed
1,065
Status unknown
384
Recruiting
233
Terminated
138
Not yet recruiting
103
Withdrawn
73

Phase

Phase 4
264
Phase 3
204
Phase 2
162
Phase 1
66
Early Phase 1
17

Where

United States
395
Egypt
218
China
139
Spain
137
Turkey
113
France
111

Who develops what

Add Infertility to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 10 programs from 8 companies, 8 with this as their studies’ main aim; 4 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Ferring Pharmaceuticals, Merck KGaA, Darmstadt, Germany and IBSA Institut Biochimique here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ProgesteroneRecent, repeated
Evidence
  • NCT07340827 · Merck KGaA, Darmstadt, Germany · Phase 3 · live · background · “Progesterone gel” · registered Jan 2026
  • NCT06091436 · Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3 · background · “Progesterone” · registered Aug 2023
  • NCT03023514 · lo li pharma · Phase 4 · background · “Vaginal Progesterone” · registered Jan 2017
  • NCT01599494 · Organon & Co. · Phase 3 · background · “Progesterone” · registered May 2012
  • NCT01225835 · Ferring Pharmaceuticals · Phase 4 · background · “Progesterone” · registered Oct 2010
IBSA Institut Biochimique SA26% of its industry studiesUS: off-patent, 13 generics marketed22 studies
Chorionic GonadotropinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06091436 · Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3 · background · “hCG” · registered Aug 2023
  • NCT05571111 · Ferring Pharmaceuticals · Phase 2 · comparator · “Novarel” · registered Sep 2022
  • NCT02449889 · Ferring Pharmaceuticals · Phase 3 · comparator · “recombinant human chorionic gonadotropin” · registered May 2015
  • NCT01863680 · Merck KGaA, Darmstadt, Germany · Phase 3 · background · “Human Chorionic Gonadotropin (hCG)” · registered May 2013
  • NCT01497197 · Merck KGaA, Darmstadt, Germany · Phase 3 · background · “Recombinant human chorionic gonadotropin (r-hCG)” · registered Dec 2011
Organon & Co.50% of its industry studies22 studies

8 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Fertilo☆ Track1 live phase-3 study: NCT06858111Gameto, Inc.
follitropin alfaApproved: EU 1995☆ Track1 live phase-3 study: NCT07340827Merck KGaA, Darmstadt, Germany
lutropin alfaApproved: EU 2000☆ Track1 live phase-3 study: NCT07340827Merck KGaA, Darmstadt, Germany
hMG subcutaneous injection☆ Track1 live phase-3 study: NCT07216742Granata Bio Corporation

The 4 in phase 3 with the nearest primary completion, of 10 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • May 2027 est.Fertilo · Gameto, Inc. · Phase 3 main aimNCT06858111 Fertilo In Vitro Research Study and Trial — primary endpoint: Demonstration of the superiority of Fertilo compared to the currently approved MediCult IVM® for infertility treatment via IVF procedures. · 500 enrolled
  • 30 Sept 2027 est.follitropin alfa, lutropin alfa · Merck KGaA, Darmstadt, Germany · Phase 3 main aim+ lutropin alfa, Cetrorelix acetate, Coriogonadotropin alfa, Progesterone gel vs Menotropinsadded to ProgesteroneNCT07340827 A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) — primary endpoint: Total number of oocytes retrieved · 266 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Infertility studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Progestins 7 open · NSAIDs 4 open · GLP-1 receptor agonists 3 open · Aromatase inhibitors 2 open · Estrogens 2 open

Coming up

106studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger. 27 (12%) take children under 18. 160 (69%) are for women only and 24 (10%) for men only; 74 (32%) take healthy volunteers.

Recruiting studies that take each age, of 233
AgeWomenMen
1019 (8%)18 (8%)
18158 (68%)63 (27%)
30201 (86%)70 (30%)
40171 (73%)69 (30%)
5057 (24%)49 (21%)
6540 (17%)36 (15%)
7538 (16%)33 (14%)
8537 (16%)33 (14%)

Across all 2,089 studies, recruiting or not: 86% stop at 75 or younger and 85% at 65; 10% take children; 82% are for women only and 5% for men only; 33% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Infertility studies take

Of 81 phase 4 interventional studies under Infertility, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 113 mo11–38 · 28 studies——
Phase 223 mo14–42 · 30 studies——
Phase 324 mo16–47 · 59 studies19 mo13–24 · 25 studies—
Phase 433 mo19–82 · 81 studies—34 mo19–82 · 74 studies
Interventional, no phase24 mo10–43 · 416 studies27 mo14–34 · 30 studies24 mo10–46 · 386 studies
Observational39 mo16–100 · 240 studies—39 mo15–100 · 209 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 2,089. Browse all 2,089 → or search them.